EDINBURGH, Scotland, Feb. 27, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the company will host a shareholder update call on Tuesday, March 5th, 2024, at 4:30 p.m. ET.
Management intends to provide a brief update on the Company's operations, clinical trials as well as insight on the company's 2024 outlook and discuss business development efforts. The Company intends to provide a forum for Q&A after remarks by CEO Bryan Kobel.
Conference Call Information:
Date: | Tuesday, March 05, 2024 |
Time: | 4:30 p.m. Eastern Time |
Live Call: | 1-877-704-4453 (U.S. Toll-Free) or 1-201-389-0920 (International) |
|
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
Last Trade: | US$0.89 |
Daily Change: | -0.02 -2.13 |
Daily Volume: | 20,092 |
Market Cap: | US$4.400M |
April 04, 2024 February 22, 2024 January 18, 2024 December 18, 2023 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB